About Coagulo
Coagulo is a company based in Newton (United States) founded in 2018. Coagulo has raised $6.5 million across 3 funding rounds from investors including Good Growth Capital, 20/20 HealthCare Partners and Sands Capital. Coagulo offers products and services including Precision-Medicine Platform and Coagulation Management System. Coagulo operates in a competitive market with competitors including BioSerenity, QuidelOrtho, NuvoAir, MedTel Healthcare and ProciseDx, among others.
- Headquarter Newton, United States
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Coagulo Medical Technologies Inc
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$6.5 M (USD)
in 3 rounds
-
Latest Funding Round
Not available
-
Investors
Good Growth Capital
& 5 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Coagulo
Coagulo offers a comprehensive portfolio of products and services, including Precision-Medicine Platform and Coagulation Management System.
Platform for analyzing clotting cascade abnormalities in medical research.
System for investigational use in detecting blood disorders.
People of Coagulo
Unlock access to complete
Unlock access to complete
Unlock access to complete
Funding Insights of Coagulo
Coagulo has successfully raised a total of $6.5M across 3 strategic funding rounds. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Coagulo
Coagulo has secured backing from 6 investors, including venture fund and institutional investors. Prominent investors backing the company include Good Growth Capital, 20/20 HealthCare Partners and Sands Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Early-stage investments are made in healthcare technology and life sciences.
|
Locked | Locked | Locked | |
|
Early-stage investments are made in life sciences and technologies.
|
Locked | Locked | Locked | |
|
Venture capital investments are provided by IAG Capital Partners.
|
Locked | Locked | Locked |
Investor details for Coagulo
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Coagulo
Investment portfolio details for Coagulo
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Coagulo
Detailed financials for Coagulo
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Coagulo Comparisons
Peer comparison for Coagulo
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Coagulo
Coagulo operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as BioSerenity, QuidelOrtho, NuvoAir, MedTel Healthcare and ProciseDx, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Provider of smart healthcare solutions for sleep and EEG lab management
|
|
| Locked | Locked | Locked |
Provider of healthcare information services
|
|
| Locked | Locked | Locked |
Clinical decision support tools for respiratory diseases are provided.
|
|
| Locked | Locked | Locked |
Remote patient monitoring software is developed for healthcare providers.
|
|
| Locked | Locked | Locked |
Point-of-care diagnostic devices for immunoassay tests are provided to clinicians.
|
|
| Locked | Locked | Locked |
ICT-based products and solutions are developed for healthcare.
|
Detailed competitors of Coagulo
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Coagulo
Complete news archive for Coagulo
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Coagulo
Coagulo was founded in 2018 and raised its 1st funding round 2 years after it was founded.
Coagulo is headquartered in Newton, United States. It is registered at Newton, Massachusetts, United States.
Jarrod Niebloom is the current CEO of Coagulo.
Coagulo is a funded company, having raised a total of $6.5M across 3 funding rounds to date.
Coagulo provides a precision-medicine platform for the diagnosis of blood coagulation disease. They provide microfluidic technology and proprietary data analytics and digital connectivity. The companys new point-of-care testing platform delivers accessible and personalized diagnosis and management of all coagulation-related diseases. The platform detects, identifies, and quantifies the effect of all anticoagulants in whole blood and communicates actionable results to healthcare providers. The software has features like the portable and automated reader, trend monitoring and treatment optimization, and personalized diagnosis and management.
Coagulo's top competitors include MedTel Healthcare, QuidelOrtho and Neurosynaptic.
Coagulo offers Precision-Medicine Platform and Coagulation Management System.
Coagulo has 6 investors. Key investors include Good Growth Capital, 20/20 HealthCare Partners, Sands Capital, IAG Capital Partners, and America’s Seed Fund.